These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 15054868)

  • 1. Improving efficacy of interleukin-12-transfected dendritic cells injected into murine colon cancer with anti-CD137 monoclonal antibodies and alloantigens.
    Tirapu I; Arina A; Mazzolini G; Duarte M; Alfaro C; Feijoo E; Qian C; Chen L; Prieto J; Melero I
    Int J Cancer; 2004 May; 110(1):51-60. PubMed ID: 15054868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
    Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
    Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation.
    Chen SH; Pham-Nguyen KB; Martinet O; Huang Y; Yang W; Thung SN; Chen L; Mittler R; Woo SL
    Mol Ther; 2000 Jul; 2(1):39-46. PubMed ID: 10899826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-CD137 monoclonal antibody administration augments the antitumor efficacy of dendritic cell-based vaccines.
    Ito F; Li Q; Shreiner AB; Okuyama R; Jure-Kunkel MN; Teitz-Tennenbaum S; Chang AE
    Cancer Res; 2004 Nov; 64(22):8411-9. PubMed ID: 15548712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spleen-derived dendritic cells engineered to enhance interleukin-12 production elicit therapeutic antitumor immune responses.
    Furumoto K; Arii S; Yamasaki S; Mizumoto M; Mori A; Inoue N; Isobe N; Imamura M
    Int J Cancer; 2000 Sep; 87(5):665-72. PubMed ID: 10925360
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratumoral injection of bone-marrow derived dendritic cells engineered to produce interleukin-12 induces complete regression of established murine transplantable colon adenocarcinomas.
    Melero I; Duarte M; Ruiz J; Sangro B; Galofré J; Mazzolini G; Bustos M; Qian C; Prieto J
    Gene Ther; 1999 Oct; 6(10):1779-84. PubMed ID: 10516729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma.
    Xu DP; Sauter BV; Huang TG; Meseck M; Woo SL; Chen SH
    Gene Ther; 2005 Oct; 12(20):1526-33. PubMed ID: 15973445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blockade of 4-1BB (CD137)/4-1BB ligand interactions increases allograft survival.
    Cho HR; Kwon B; Yagita H; La S; Lee EA; Kim JE; Akiba H; Kim J; Suh JH; Vinay DS; Ju SA; Kim BS; Mittler RS; Okumura K; Kwon BS
    Transpl Int; 2004 Aug; 17(7):351-61. PubMed ID: 15349720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-mediated protective immunity in Her-2/neu transgenic mice.
    Cuadros C; Dominguez AL; Lollini PL; Croft M; Mittler RS; Borgström P; Lustgarten J
    Int J Cancer; 2005 Oct; 116(6):934-43. PubMed ID: 15856473
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combinatorial therapy for liver metastatic colon cancer: dendritic cell vaccine and low-dose agonistic anti-4-1BB antibody co-stimulatory signal.
    Lee H; Park HJ; Sohn HJ; Kim JM; Kim SJ
    J Surg Res; 2011 Jul; 169(1):e43-50. PubMed ID: 21571303
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
    Kim JA; Averbook BJ; Chambers K; Rothchild K; Kjaergaard J; Papay R; Shu S
    Cancer Res; 2001 Mar; 61(5):2031-7. PubMed ID: 11280763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T cell activation with systemic agonistic antibody versus local 4-1BB ligand gene delivery combined with interleukin-12 eradicate liver metastases of breast cancer.
    Martinet O; Divino CM; Zang Y; Gan Y; Mandeli J; Thung S; Pan PY; Chen SH
    Gene Ther; 2002 Jun; 9(12):786-92. PubMed ID: 12040460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-CD137 monoclonal antibody promotes the direct anti-tumor effect mediated by peripheral blood-derived human dendritic cells in vitro.
    Zhang L; Wang Q; Wang X; Ding P; Song J; Ma C; Sun W
    Cell Mol Immunol; 2004 Feb; 1(1):71-6. PubMed ID: 16212924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engagement of the CD137 (4-1BB) costimulatory molecule inhibits and reverses the autoimmune process in collagen-induced arthritis and establishes lasting disease resistance.
    Foell JL; Diez-Mendiondo BI; Diez OH; Holzer U; Ruck P; Bapat AS; Hoffmann MK; Mittler RS; Dannecker GE
    Immunology; 2004 Sep; 113(1):89-98. PubMed ID: 15312139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD137 costimulatory T cell receptor engagement reverses acute disease in lupus-prone NZB x NZW F1 mice.
    Foell J; Strahotin S; O'Neil SP; McCausland MM; Suwyn C; Haber M; Chander PN; Bapat AS; Yan XJ; Chiorazzi N; Hoffmann MK; Mittler RS
    J Clin Invest; 2003 May; 111(10):1505-18. PubMed ID: 12750400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic vaccination with tumor cells that engage CD137.
    Hellstrom KE; Hellstrom I
    J Mol Med (Berl); 2003 Feb; 81(2):71-86. PubMed ID: 12601523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Local administration of IL-12-transfected dendritic cells induces antitumor immune responses to colon adenocarcinoma in the liver in mice.
    Satoh Y; Esche C; Gambotto A; Shurin GV; Yurkovetsky ZR; Robbins PD; Watkins SC; Todo S; Herberman RB; Lotze MT; Shurin MR
    J Exp Ther Oncol; 2002; 2(6):337-49. PubMed ID: 12440225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity.
    Tatsumi T; Huang J; Gooding WE; Gambotto A; Robbins PD; Vujanovic NL; Alber SM; Watkins SC; Okada H; Storkus WJ
    Cancer Res; 2003 Oct; 63(19):6378-86. PubMed ID: 14559827
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-CD137 antibodies in the treatment of autoimmune disease and cancer.
    Mittler RS; Foell J; McCausland M; Strahotin S; Niu L; Bapat A; Hewes LB
    Immunol Res; 2004; 29(1-3):197-208. PubMed ID: 15181282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibodies directed against the T-cell activation molecule CD137 (interleukin-A or 4-1BB) block human lymphocyte-mediated suppression of tumor xenografts in severe combined immunodeficient mice.
    Sabel MS; Conway TF; Chen FA; Bankert RB
    J Immunother; 2000; 23(3):362-8. PubMed ID: 10838665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.